Triple oral fixed-dose diabetes polypill versus insulin plus metformin efficacy demonstration study in the treatment of advanced type 2 diabetes (TrIED study-II)

Diabetes, Obesity and Metabolism

Volumn 13, Issue 9, 2011, Pages 800-805

  Bell, D S H ^a   Dharmalingam, M ^b   Kumar, S ^c   Sawakhande, R B ^d  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^b M S RAMAIAH MEDICAL COLLEGE   (India)

^c SIR GANGA RAM HOSPITAL   (India)

^d MUHS   (India)

Author keywords

Metformin; Sulphonylureas; Thiazolidinediones; Type 2 diabetes

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C PEPTIDE; CREATININE; GLIMEPIRIDE PLUS METFORMIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HUMAN INSULIN; INSULIN PLUS METFORMIN PLUS PIOGLITAZONE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; ORAL ANTIDIABETIC AGENT; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ASSESSMENT; CLINICAL PRACTICE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC PATIENT; DIET RESTRICTION; DISEASE DURATION; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEG EDEMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; POSTPRANDIAL STATE; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SUSTAINED DRUG RELEASE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT REFUSAL; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

EID: 79960796303     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2011.01408.x     Document Type: Article

References (16)

1. Bell DS. Triple oral therapy for type 2 diabetes. Diabetes Res Clin Pract 2007; 78: 313-315.
2. Ovalle F, Bell DS. Triple oral antidiabetic therapy in type 2 diabetes mellitus. Endocr Pract 1998; 4: 146-147.
3. Bell DS. Why I initiate with two insulin sensitizers in patients with type 2 diabetes. Endocr Pract 2003; 9: 96-101.
4. Anand Moses CR, Shanmugam A, Suresh E, Mahadevan V. Triple oral therapy of fixed dose combination (FDC) of glimepiride + metormin SR + pioglitazone vs Insulin 70/30 mix and metformin SR Efficacy Demonstration study in the treatment of insulin-naÏve patients with type 2 diabetes mellitus inadequately controlled on dual therapy of glimepiride and metformin prescribed separately or as FDC (TrIED-I study). Indian Pract 2008; 61: 1-9.
5. Meshram DM, Langade DG, Kinagi SB, Naikwadi AA, Morye V, Chopra D. Evaluation of efficacy and safety of fixed dose combination of glimepiride 2 mg pluspioglitazone 15 mg plus metformin SR 500 mg in the management of patients with type-2 diabetes mellitus. J Indian Med Assoc 2005; 103: 447-450.
6. Gavin LA, Barth D, Arnold R, Shaw R. Troglitazone add-on therapy to a combination of sulfonlyureas plus metformin achieved and maintained effective diabetes control. Endocr Pract 2000; 6: 306-310.
7. Hershon KS, Hershon PM. Primary, secondary, tertiary, and quaternary treatment with troglitazone in type 2 diabetes mellitus in an outpatient clinical practice. Endocr Pract 2000; 6: 20-25.
8. Dailey GE 3rd, Noor MA, Park JS, Bruce S, Fiedorek FT. Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial. Am J Med 2004; 116: 223-229.
9. Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care 2006; 29: 554-559.
10. Reynolds LR, Kingsley FJ, Karounos DG, Tannock LR. Differential effects of rosiglitazone and insulin glargine on inflammatory markers, glycemic control, and lipids in type 2 diabetes. Diabetes Res Clin Pract 2007; 77: 180-187.
11. Roberts VL, Stewart J, Issa M, Lake B, Melis R. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled parallel-group study. Clin Ther 2005; 27: 1535-1547.
12. Ovalle F, Bell DS. Effect of rosiglitazone versus insulin on the pancreatic beta-cell function of subjects with type 2 diabetes. Diabetes Care 2004; 27: 2585-2589.
13. Bell DS, Ovalle F. Long-term glycaemic efficacy and weight changes associated with thiazolidinediones when added at an advanced stage of type 2 diabetes. Diabetes Obes Metab 2006; 8: 110-115.
14. Hertz RP, Unger AN, Lustik MB. Adherence with pharmacotherapy for type 2 diabetes: a retrospective cohort study of adults with employer-sponsored health insurance. Clin Ther 2005; 27: 1064-1073.
15. Ho PM, Spertus JA, Masoudi FA et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med 2006; 166: 1842-1847.
16. Swinnen SG, Devries JH. Contact frequency determines outcome of basal insulin initiation trials in type 2 diabetes. Diabetologia 2009; 52: 2324-2327.